Touchlight shortlisted for London Award for Innovation
We are delighted to announce that Touchlight has been shortlisted for the London Award for Innovation in the 25th Anniversary London First Awards. See full article here.
London First are a non-profit organisation with the mission to make London the best city in the world to do business. They aim to influence national and local government policies and investment decisions to support London’s global competitiveness.
London First hosts an annual awards black tie dinner to reward and mark key individuals, activities, companies and projects that have contributed to making London the best city in the world in which to work, study and play.
The award winner will be chosen from the shortlist of three based on a public vote, and the winner will be announced at the awards dinner on the 25th of January. Support Touchlight’s nomination by voting here. Voting closes 9th December.
- ENDS -
Touchlight is a privately-owned biotechnology company based in London, U.K., focussed on the discovery and development of DNA-based genetic medicines, including DNA vaccines and gene therapies. Touchlight has developed a novel, synthetic DNA vector known as “doggybone DNA” or dbDNA™.
dbDNA™ is a minimal, linear, covalently closed structure, that eliminates bacterial sequences. Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies.
Touchlight is applying dbDNA across advanced therapeutic modalities, both in-house and with partners. The company also provides contract manufacturing capabilities to produce dbDNA as a critical starting material for advanced therapy production through its manufacturing arm, Touchlight DNA Services.
Issued for and on behalf of Touchlight by Instinctif Partners.
For more information please contact:
|Jonny Ohlson, CEO||Tim Watson|
|Robin Bodicoat, Head of Marketing||Agnes Stephens|
|E: email@example.com||E: firstname.lastname@example.org|
|T: +44 20 8481 9200||T: +44 20 7457 2020|